• We are dedicated to supporting the discovery and development of novel diagnostics and therapeutic targets that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and therapeutic targets that help to save lives and improve the quality of life of cancer patients.
  • We are fuelled by tissue-based Dx test development and validation. We are fuelled by tissue-based Dx test development and validation.
  • We wish to collaborate with partners focused on cancer drug development. Let's start the Rx-Dx process early. We wish to collaborate with partners focused on cancer drug development. Let's start the Rx-Dx process early.
  • Our biomarker DISCOVERY focus is to identify biomarkers and therapeutic targets for cancer. Our biomarker DISCOVERY focus is to identify biomarkers and therapeutic targets for cancer.
  • Our biomarker DETECTION focus uses our IHC-MARK software tool and other off-the-shelf algorithms to make automated quantitation easy. Our biomarker DETECTION focus uses our IHC-MARK software tool and other off-the-shelf algorithms to make automated quantitation easy.
  • AngioTox will predict which patients are prone to cancer drug toxicity side effects AngioTox will predict which patients are prone to cancer drug toxicity side effects
  • FAST-PATH will create faster tools to diagnose Prostate Cancer FAST-PATH will create faster tools to diagnose Prostate Cancer
  • AngioPredict will predict which cancer patients will respond positively to treatment AngioPredict will predict which cancer patients will respond positively to treatment
  • RATHER targets untreatable and aggressive forms of Breast Cancer RATHER targets untreatable and aggressive forms of Breast Cancer
  • Target Melanoma will provide greater understanding of the most aggressive type of skin cancer (Melanoma) Target Melanoma will provide greater understanding of the most aggressive type of skin cancer (Melanoma)
  • APO-DECIDE will create comprehensive tools and tests to predict which patients will benefit from chemotherapy APO-DECIDE will create comprehensive tools and tests to predict which patients will benefit from chemotherapy

Partnering

OncoMark PartneringOncoMark has invested in R&D and in-licensing of IP for diagnostic assay development. We believe that Rx-Dx partnering should begin as early as possible in the development process.

Every winning partnership starts with a simple decision Click for more details »

Products

IHC-Mark and Biomarker Interpretation Workflow OncoMark has developed proprietary Prognostic & Predictive Biomarkers panels. Our research validated software IHC-Mark provides automated nuclear, cytoplasmic and membraneous IHC stain quantitation.
Another time-saving product is our Biomarker Interpretation Workflow platform. We also have a range of new assays & IP in development.

View current products »
 

Research Projects



 

 

Subscribe to RSS FeedCompany News

OncoMark researchers present their data at the International Melanoma Workshop, May 2013
Two OncoMark researchers presented their data at the International Melanoma Workshop in the UCD Conway Institute in May. This conference was jointly organised by UCD and OncoMark, and attracted high-profile speakers in the melanoma field. » read more
OncoMark commissions an introductory video
Oncomark has commissioned a short video to introduce the company to a wider audience. To view please select the following link. http://vimeo.com/65377045 » read more
April 2013: OncoMark presents at American Association for Cancer Research (AACR)
OncoMark researcher Karin van den Hurk presented data from the Target Melanoma project at the recent Annual Meeting of the American Association for Cancer Research (AACR), 6th - 12th April in Washington, DC. She presented novel data showing that the BRAFV600E mutation is less common among patients with melanoma in Ireland. Karin also presented at the Irish Association for Cancer Research (IACR) conference (Dublin, 27th of Feb - 1st March 2013). » read more

Subscribe to RSS FeedIndustry News

April 2013: Colorectal cancers predicted to rise by 45% by 2020 (www.irishtimes.com)
The number of Irish people suffering from colorectal cancer is predicted to increase by 34 per cent in women and 45 per cent in men by 2020, according to a report published today by the National Cancer Registry. The report "Colorectal Cancer Incidence, Mortality, Treatment and Survival in Ireland: 1994 - 2010" found the number of male cases increased from 983 in 1994 to 1343 in 2010 and the number of female cases increased from 769 in 1994 to 955 in 2010. » read more
Feb 2013: Melanoma: Finding the One-Two Punch that works (www.pharmacytimes.com)
 A test of combinations of hundreds of agents, including statins, on metastatic melanoma cells found a number of combinations that showed promise. » read more
March 2013: Wide Consensus Reached at Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine
Wide consensus emerged at the Irish Presidency Conference on 'Innovation and Patient Access to Personalised Medicine' on the need for radical change if Europe's approach to healthcare is to benefit from the potential of personalised medicine. Declaring his support for the innovative responses that personalised medicine can offer to the challenges faced by health systems, Irish Health Minister James Reilly warned: "We are losing a lot of research from Europe because of red tape". » read more